Bitopertin
Small molecule
Also known as RG1678, RO4917838, DISC-0998
Evidence outlook · regulatory review
Erythropoietic Protoporphyria: FDA issued a complete response letter (2026-02-13)
FDA issues complete response letter for the bitopertin NDA in erythropoietic protoporphyria. A complete response letter means the application was not approved as filed; the sponsor may resubmit. The event is listed under Regulatory events.
Company guidance: regulatory filing expected by the end of 2026 (NCT06910358; Disc Medicine, 5 Nov 2026). “We reported positive topline results from APOLLO in October 2026, and plan to engage with the FDA and resubmit an NDA by the end of 2026.” Source ↗
Company guidance: topline data expected Q4 2026 (NCT06910358; Disc Medicine, 30 Jul 2026). “Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
APOLLO NCT06910358 · Erythropoietic Protoporphyria Registry: NCT06910358 | 3 | Average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) after 6 months (24 weeks) of treatment; Percent change from baseline in whole-blood metal-free PPIX levels at 6 months (24 weeks); Safety and tolerability, as assessed by adverse events (AEs) and laboratory results, over the 6-month treatment period (24 weeks) 2026-09-08 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 1 more trial
NCT05883748 NCT05883748 · Erythropoietic Protoporphyria Registry: NCT05883748 | 2/3 | Incidence of treatment-emergent adverse events (up to 5 Years); Incidence of clinically abnormal vital signs (up to 5 Years); Incidence of clinically abnormal physical exam (up to 5 Years); Incidence of abnormal laboratory test results (up to 5 Years); Assessment of Patient Health Questionnaire (PHQ-8) (up to 5 Years); Assessment of C-SSRS (up to 5 Years) 2028-06 | In progress: results expected 1 Jun 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Bitopertin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
June 2028 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent